Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trivalent inactivated influenza vaccine (TIV) and FluMist are two distinct types of flu vaccines. TIV is an injectable vaccine containing three inactivated (killed) strains of the influenza virus—typically one A(H1N1), one A(H3N2), and one B lineage strain. It works by stimulating the immune system to produce antibodies against these viral proteins without causing disease. TIV is administered via intramuscular injection and is suitable for a wide range of age groups[1][3][7]. FluMist is a brand name for the live attenuated influenza vaccine (LAIV), which contains weakened but live forms of the same three or four strains found in other flu vaccines. It is delivered as a nasal spray and induces immunity by mimicking natural infection at mucosal surfaces where respiratory viruses enter[4][6]. FluMist stimulates both mucosal and systemic immune responses. TIV has been widely used for decades; LAIV/FluMist was developed as an alternative for those who prefer needle-free vaccination or have needle phobia. Both are indicated primarily for prevention of seasonal influenza.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal).